J&J Says Ultram Titration Schedule Was Developed To Improve Safety Profile
Executive Summary
A titration dosing regimen for Johnson & Johnson's analgesic Ultram was added to the non-titrated dosing schedule in labeling in order to reduce adverse events, J&J told FDA
You may also be interested in...
Ultram Pain Indication Cannot Be Divided, J&J Says In Response To Teva
The indication for Ultram (tramadol) cannot be divided into chronic versus acute pain to justify omission of patent-protected titration dosing from generic labeling, Johnson & Johnson told FDA
Ultram Pain Indication Cannot Be Divided, J&J Says In Response To Teva
The indication for Ultram (tramadol) cannot be divided into chronic versus acute pain to justify omission of patent-protected titration dosing from generic labeling, Johnson & Johnson told FDA
Glucophage Generics Enter Market: Bristol Says It Will Not Sue Agency
Generic versions of metformin will carry labeling that refers prescribers to Bristol-Myers Squibb's Glucophage label for information on pediatric patients